Extending anti-HER2 treatment after breast cancer surgery
Treatments studied
Part of Cancer clinical trials.
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your breast cancer is invasive and HER2-positive (confirmed by pathology)
- You finished trastuzumab or T-DM1 within the last 3 years
- You can do daily activities well (ECOG performance status 0–1)
- Your heart, liver, kidneys, and other organ tests are adequate
- You can take tablets by mouth and absorb them properly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.